Biblio Discovery — Demo Discovery Service

6 hasil untuk "Matthieu Texier"

Menampilkan 1–6 · 0,18 detik · RSS

  1. Artikel Jurnal

    Plasma galectins and metabolites in advanced head and neck carcinomas: evidence of distinct immune characteristics linked to hypopharyngeal tumors

    Bao-Tram Thi Tran; Aurore Gelin; Sylvère Durand dkk.

    OncoImmunology, Vol. 12 No. 1 · 2023 · Inggris · DOAJ Scopus

    Extra-cellular galectins 1, 3 and 9 (gal-1, −3 and −9) are known to act as soluble immunosuppressive agents in various malignancies. Previous publications have suggested that their expression is dependent on the metabolic status of producing cells and reciprocally that they can influence metabolic…

  2. Artikel Jurnal

    An international phase II trial and immune profiling of SBRT and atezolizumab in advanced pretreated colorectal cancer

    Antonin Levy; Daphné Morel; Matthieu Texier dkk.

    Molecular Cancer, Vol. 23 No. 1 · 2024 · Inggris · DOAJ Scopus

    Abstract Background Immuno-radiotherapy may improve outcomes for patients with advanced solid tumors, although optimized combination modalities remain unclear. Here, we report the colorectal (CRC) cohort analysis from the SABR-PDL1 trial that evaluated the PD-L1 inhibitor atezolizumab in…

  3. Artikel Jurnal

    Monocyte-lineage tumor infiltration predicts immunoradiotherapy response in advanced pretreated soft-tissue sarcoma: phase 2 trial results

    Antonin Levy; Daphné Morel; Matthieu Texier dkk.

    Signal Transduction and Targeted Therapy, Vol. 10 No. 1 · 2025 · Inggris · DOAJ Scopus

    Abstract Immunoradiotherapy holds promise for improving outcomes in patients with advanced solid tumors, including in soft-tissue sarcoma (STS). However, the ideal combination of treatment modalities remains to be determined, and reliable biomarkers to predict which patients will benefit are…

  4. Artikel Jurnal

    Safety, recommended dose, efficacy and immune correlates for nintedanib in combination with pembrolizumab in patients with advanced cancers

    Capucine Baldini; Francois-Xavier Danlos; Andreea Varga dkk.

    Journal of Experimental & Clinical Cancer Research, Vol. 41 No. 1 · 2022 · Inggris · DOAJ Scopus

    Abstract Background We aimed to determine the safety and efficacy of nintedanib, an oral anti-angiogenic tyrosine kinase inhibitor, in combination with pembrolizumab, an anti-PD1 immunotherapy, in patients with advanced solid tumors (PEMBIB trial; NCT02856425). Methods In this monocentric phase Ib…